Doz

Insulin lispro

انسولین لیسپرو

⚠ Unverified

🍽️ Alimentary Tract And MetabolismRapid-acting insulin

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA020563ATC A10AB04

Market / country: 🇺🇸 USA

Humalog (US)

🧮 Dose calculator

Type 1 diabetes · Regimen source: FDA Humalog · 2.3FDA Humalog · 2.1

⛔ Label: individualise by metabolic needs, glucose monitoring and goals. SC within 15 min before or right after a meal; usually with a basal insulin. U-200 only in its own pen. FDA Humalog · 2.3FDA Humalog · 2.1

🛡️ Safety & information

Contraindications

  • ⛔ During episodes of hypoglycaemia; hypersensitivity to the insulin or its excipients. FDA Humalog · 4

Warnings

Formulations

  • 100 units/mL (U-100) vial, cartridge or KwikPen — injection 🇺🇸 USA FDA Humalog · 3
  • 200 units/mL (U-200) KwikPen — injection 🇺🇸 USA FDA Humalog · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Humalog · 8.1

    “Risk Summary Published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) .”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Humalog · 8.2

    “Risk Summary Available data from published literature suggests that exogenous human insulin products, including insulin lispro, are transferred into human milk.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Humalog · 8.4

    “The safety and effectiveness of HUMALOG to improve glycemic control have been established in pediatric patients with diabetes mellitus.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Humalog · 8.5

    “Of the total number of patients (n=2,834) in eight clinical studies of HUMALOG, twelve percent (n=338) were 65 years of age or over.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav